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Abstract
Background: Disulfide bonds are one of the most common post-translational modifications found in proteins. The
production of proteins that contain native disulfide bonds is challenging, especially on a large scale. Either the
protein needs to be targeted to the endoplasmic reticulum in eukaryotes or to the prokaryotic periplasm. These
compartments that are specialised for disulfide bond formation have an active catalyst for their formation, along
with catalysts for isomerization to the native state. We have recently shown that it is possible to produce large
amounts of prokaryotic disulfide bond containing proteins in the cytoplasm of wild-type bacteria such as E. coli by
the introduction of catalysts for both of these processes.
Results: Here we show that the introduction of Erv1p, a sulfhydryl oxidase and a disulfide isomerase allows the
efficient formation of natively folded eukaryotic proteins with multiple disulfide bonds in the cytoplasm of E. coli.
The production of disulfide bonded proteins was also aided by the use of an appropriate fusion protein to keep
the folding intermediates soluble and by choice of media. By combining the pre-expression of a sulfhydryl oxidase
and a disulfide isomerase with these other factors, high level expression of even complex disulfide bonded
eukaryotic proteins is possible
Conclusions: Our results show that the production of eukaryotic proteins with multiple disulfide bonds in the
cytoplasm of E. coli is possible. The required exogenous components can be put onto a single plasmid vector
allowing facile transfer between different prokaryotic strains. These results open up new avenues for the use of
E. coli as a microbial cell factory.
Background
Disulfide bonds are covalent linkages formed between
two cysteine residues in proteins. Around one-third of all
human proteins fold in the endoplasmic reticulum (ER)
and acquire disulfide bonds there. The formation of
native disulfide bonds is often the rate limiting step
of protein biogenesis [1-3]. Due to this the production
of proteins that contain disulfide bonds is difficult,
especially on a large scale.
In compartments where disulfide bond formation
naturally occurs there are two distinct steps in
biosynthesis, catalysis of de novo disulfide bond forma-
tion and subsequent rearrangement or isomerization to
generate native disulfide bonds. In order to produce dis-
ulfide bond containing proteins in the cytoplasm of
E. coli a variety of strains have been produced [4-11].
These are available commercially under the names ori-
gami or rosetta-gami (Novagen) or SHuffle (New Eng-
land Biolabs) and have the common feacture that they
are Δgor ΔtrxB strains and hence have both of the disul-
fide bond reducing pathways in the cytoplasm disrupted.
The SHuffle system also expresses DsbC in the cyto-
plasm as a catalyst of disulfide bond isomerization.
While these systems generate disulfide bond containing
proteins, the yields are often very low as there is no cat-
alyst of de novo disulfide bond formation present.
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Recently we showed that the introduction of a sulfhy-
dryl oxidase, a natural catalyst of de novo disulfide bond
formation, into the cytoplasm of E. coli allowed efficient
production of disulfide bond containing prokaryotic
proteins even without disruption of the reducing path-
ways [12]. In particular we used the sulfhydryl oxidase
Erv1p from the inter-membrane mitochondrial space of
S. cerevisiae.
Here we show that the introduction of Erv1p along
with a catalyst of disulfide bond isomerization into the
cytoplasm of wild-type E. coli results in efficient produc-
tion of eukaryotic disulfide bond containing proteins. By
combining the pre-expression of these two catalysts of
native disulfide bond formation with methods to keep
folding intermediates soluble and alternative growth
media, expression levels of active complex proteins such
as the nine disulfide bond containing vtPA from growth
in shake flasks are over 800-fold greater than previously
reported. These results open up new possibilities for the
production of disulfide bond containing proteins in high
yields in E. coli.
Results
Production of a tissue plasminogen activator fragment
Our previous systems using Erv1p as a catalyst of disul-
fide bond formation in the cytoplasm of E. coli were
based on screening for an increase in yield of active E.
coli alkaline phosphatase (PhoA; 2 disulfides) and E. coli
Phytase (AppA; 4 disulfides). While these results showed
that disruption of reducing pathways is not essential for
efficient disulfide bond formation in the cytoplasm of E.
coli and that high yields of active proteins were possible
[12], we wanted to see if the use of Erv1p would allow
for the production of more challenging proteins of
eukaryotic origin.
Tissue plasminogen activator is a protease that con-
verts plasminogen to plasmin and is used to treat pul-
monary embolism, myocardial infarction and stroke.
Retavase, one of the commercially available preparations,
is a fragment of tissue plasminogen activator which con-
tains only the kringle 2 and protease domains and as
such it contains nine disulfide bonds. This fragment,
also known as vtPA, has previously been used to charac-
terize disulfide bond formation in the cytoplasm of E.
coli [5]. Expression of vtPA in E. coli results in the for-
mation of inactive inclusion bodies. While expression of
vtPA in the Δgor ΔtrxB strain rosetta-gami results in a
small gain of activity (Figure 1A and see additional file
1: Table of vtPA production and activity data), as per
previously published results [5], the protein is still pre-
dominantly found in the insoluble fraction. Since vtPA
contains a significant number of non-sequential disulfide
bonds a disulfide isomerase is required for the more
efficient formation of native disulfide bonds. The
co-expression of the periplasmic disulfide isomerase
DsbC in the cytoplasm of the Δgor ΔtrxB strain resulted
in a significant increase in the amount of active protein
produced (Figure 1A and see additional file 1: Table of
vtPA production and activity data), as per previous
results with vtPA derivatives [5]. While no significant
activity could be seen for vtPA with or without co-
expression of mature DsbC in a strain with the reducing
pathways intact, co-expression of Erv1p and mature
DsbC in this strain resulted in the production of active
vtPA at comparable levels to that seen in the Δgor
ΔtrxB strain with co-expression of mature DsbC alone
(Figure 1A and see additional file 1: Table of vtPA pro-
duction and activity data). Hence the disruption of
genes involved in the reducing pathways in the cyto-
plasm is not obligatory for the production of even a
complex disulfide bonded eukaryotic protein. However,
in contrast to the results we previously observed for
PhoA and AppA [12], the effects of co-expression of an
active catalyst of disulfide bond formation were additive
Figure 1 Production of vtPA in the cytoplasm of E. coli .
A) Relative yields of active vtPA produced in LB media at 30°C,
normalized to the equivalent of the best previously reported system
(a Δgor ΔtrxB strain with co-expression of mature DsbC) and shown
as mean ± s.d. (n = 4-12; see additional file 1: Table of vtPA
production and activity data). Strains: BL = BL21 (DE3) pLysSRARE;
RG = rosetta-gami; OG = origami. When present Erv1p and mature
DsbC are co-expressed from a polycistronic vector. B) SDS-PAGE
analysis of MBP-fusion vtPA in LB media. T = total E. coli lysate, S =
soluble fraction. The position of MBP-vtPA is marked with an arrow.
Note the difference in expression levels in rosetta-gami compared
with origami due to the expression of rare tRNAs.
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with disruption of the reducing pathways for vtPA (Fig-
ure 1A and see additional file 1: Table of vtPA produc-
tion and activity data). While these results indicate that
it is possible to increase the yield of active protein pro-
duced 5-fold over previously published results, we noted
that a significant proportion of the vtPA produced was
in mixed disulfide oligomers and hence not correctly
folded (data not shown).
Production of a tissue plasminogen activator fragment
fusion protein
It is known that the production of proteins as fusion
proteins can increase the solubility of the protein and
hence increase the yield. This may be especially relevant
to the production of disulfide bond containing proteins
since the formation of the native state is slower, due to
the requirement to form native disulfides, and hence the
folding intermediates, which are usually considered to
be more prone to aggregation than the native state, are
longer lasting. We chose to use maltose binding protein
(MBP) as a fusion partner since it contains no cysteine
residues and hence cannot form additional non-native
disulfide bonds and since it has been reported to be
very efficient at increasing the yields of heterologously
expressed proteins [13]. The expression of vtPA as a
MBP fusion resulted in increased levels of active protein
being produced when either Erv1p was co-expressed or
the protein was expressed in the Δgor ΔtrxB strain,
again with these effects being additive for vtPA (Figure
1A and see additional file 1: Table of vtPA production
and activity data). Combining these, along with co-
expression of a disulfide isomerase, resulted in activity
levels circa 20-fold higher than that of co-expression of
DsbC in a Δgor ΔtrxB strain and a concomitant increase
in the yield of soluble protein (Figure 1B). While this is
a very significant increase in active protein production,
analysis of the vtPA produced suggested that a signifi-
cant proportion of the material was still not correctly
folded.
Development of a pre-expression vector for Erv1p and a
disulfide isomerase
We thought that co-expression of the Erv1p and/or dis-
ulfide isomerase might be an issue for MBP-vtPA pro-
duction. The first MBP-vtPA produced would
experience low to non-existent levels of these folding
factors and hence would not be able to fold correctly,
and misfolding/aggregation is an auto-catalytic process.
To circumvent this issue we made constructs which
expressed either Erv1p alone or Erv1p and a disulfide
isomerase from an arabinose promoter system (Figure
2). Such a system allows pre-expression of these folding
factors. The use of such a two-step expression system
for chaperone and folding catalyst production has
previously been reported to beneficial for the production
of soluble folded recombinant protein [14]. Due to a
lack of available information on the plasmid pLysSRARE
found in rosetta-gami strains we decided to use pLysS
as the backbone for this new vector. Hence experiments
undertaken with the pre-expression plasmid results in
no over-expression of the rare tRNAs found on pLysS-
RARE. This has an effect on reducing the amount of
vtPA produced ([15] and Figure 1B). Despite this effect,
pre-expression of Erv1p (data not shown) or dual
expression of Erv1p and DsbC resulted in a significant
increase (p < 0.01; two-tailed T-test of two samples of
unequal variance) in the amount of active vtPA pro-
duced compared to co-expression, with circa 30-fold
higher levels of activity compared with the non-MBP
tagged protein in rosetta-gami with co-expression of
DsbC (Figure 3 and see additional file 1: Table of vtPA
production and activity data, including direct compari-
son of pre- and co-expression in origami in EnBase
media).
Media effects on the yield of active vtPA
The production of proteins in prokaryotic systems is
often very dependent on the media used. We therefore
wanted to compare our expression system with that in
the corresponding Δgor ΔtrxB strain in different media.
Recently an ingenious media, marketed under the name
EnBase (Biosilta Oy), has been reported which allows
high density growth of E. coli cultures in shake-flasks
via the controlled release of an utilizable carbon source
[16]. The activity levels of vtPA produced in EnBase
show similar overall patterns when compared to produc-
tion in LB. However the relative activity per final OD600
of the culture was significantly increased in all compari-
sons made of vtPA expression (Figure 4A and see addi-
tional file 1: Table of vtPA production and activity data).
The highest relative activity per OD600 of the final cul-
ture was MBP-tagged vtPA with pre-expression of Erv1p
and DsbC which resulted in a circa 100-fold increase in
relative activity c.f. the non-MBP tagged protein in
rosetta-gami with co-expression of DsbC i.e. the best
previously reported [7]. This increase in activity is possi-
bly due to the slow bacterial growth in this media after
induction [16] and hence the reduced rate of protein
synthesis which decreases the probability of folding
intermediates interacting with each other. In addition to
this effect, the final optical density of cultures grown in
shake flasks is circa 10-fold higher in EnBase media
compared to the corresponding strains grown in LB
media and hence the yields of active protein produced
are up to 800-fold over the equivalent of the best pre-
viously reported in shake flasks (Figure 4B). While
highly-active fully soluble monomeric MBP-vtPA can be
produced in our system, the protein produced was still
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not homogenously correctly folded and after purification
and cleavage of the MBP tag the vtPA had a tendency
to aggregate making quantification and analysis of the
protein produced difficult.
Production of other eukaryotic proteins with multiple
disulfide bonds
In addition to pre-expression of the folding factors being
more efficient than co-expression, the synthesis of a
pre-expression vector for Erv1p or Erv1p and a disulfide
isomerase in theory obviates the need to make polycistro-
nic vectors for their co-expression with target proteins,
increasing their ease of use and facilitating transfer
between different prokaryotic strains. To test this we
examined the expression of a range of disulfide bond
containing eukaryotic proteins in strains pre-expressing
Erv1p and a disulfide isomerase from out pLysS-arabi-
nose promoter based plasmids.
Bovine pancreatic trypsin inhibitor (BPTI) is widely
used as a model protein for examining disulfide bond
formation in vitro [17-19]. The mature form is only 58
amino acids in size and contains three non-sequential
disulfide bonds. We were interested in producing large
amounts of mutants of BPTI that contain two disulfide
Figure 2 Design of the plasmids for pre- and co-expression of Erv1p and/or a protein disulfide isomerase. Co-expression is based on a
polycistronic vector based on pET23 with a T7 promoter/terminator and IPTG induction. Pre-expression is based on cloning the Erv1p +/- the
disulfide isomerase into an arabinose inducible system cloned into pLysS. Since the vector map for pLysSRARE is not available we were unable
to clone into this vector and hence when using a Δgor ΔtrxB strain the co-expression studies are done in an origami rather than rosetta-gami
background.
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bonds and mimic known folding intermediates for
another project. In particular we wanted to produce a
C14A/C38A mutant, which mimics the C5-C55/C30-
C51 folding intermediate and the C30A/C51A mutant,
which mimics the C5-C55/C14-C38 intermediate (note
that the numbering used for BPTI follows the literature
standard with numbering based on the mature protein
sequence). Both species are thought to be major inter-
mediates in the folding pathway [17] and contain two of
the three disulfide bonds found in the native protein.
When expressed in the cytoplasm of wild-type E. coli or
the Δgor ΔtrxB strain rosetta-gami both mutants form
inclusion bodies. In contrast when these mutants, or
wild-type BPTI, are expressed in origami with pre-
expression of Erv1p and mature PDI soluble protein is
produced (Figure 5A). Purification and analysis of the
C14A/C38A or C30A/C51A BPTI mutants revealed that
both purified proteins were monomeric (data not
shown), with their elution points from analytical reverse
phase HPLC being equivalent to the relevant two disul-
fide containing wild-type folding intermediate (Figure
5B), indicating that only a single correctly folded disul-
fide bonded species is obtained. In contrast, when other
mutants of BPTI were expressed that should mimic
folding intermediates with one native and one non-
native disulfide [18] e.g. C14A/C55A or C38A/C55A, no
soluble protein was obtained under any conditions
tested (data not shown). While fully soluble correctly
folded BPTI mutants were produced upon pre-expres-
sion of Erv1p and mature PDI, pre-expression of Erv1p
and mature DsbC under the same conditions resulted in
a mixture of species, with only circa 50% of the protein
correctly folded and the remainder forming inclusion
Figure 3 The effect of co- vs pre-expression of folding factors
on the production of vtPA in the cytoplasm of E. coli. Relative
yields of active MBP-vtPA produced in LB media at 30°C, normalized
to the equivalent of the best previously reported system (a Δgor
ΔtrxB strain with co-expression of mature DsbC) and shown as
mean ± s.d. (n = 4-12; see additional file 1: Table of vtPA
production and activity data). Strains: RG = rosetta-gami; OG =
origami. For Erv1p and mature DsbC expression + = co-expression
while +p = pre-expression. Note the increase in vtPA activity with
pre-expression comes despite the significant reduction in vtPA
expression levels in rosetta-gami compared with origami due to the
expression of rare tRNAs (figure 1B).
Figure 4 Effects of media on vtPA production in the cytoplasm of E. coli. Panel A) Relative fold activity of vtPA produced in EnBase media
at 30°C, normalized to the equivalent of the best previously reported system (rosetta-gami with co-expression of mature DsbC) and shown as
mean ± s.d. (n = 2-6; see additional file 1: Table of vtPA production and activity data). Strains: BL = BL21 (DE3) pLysSRARE; RG = rosetta-gami;
OG = origami. For Erv1p and mature DsbC expression + = co-expression while +p = pre-expression. Panel B) Relative yields of active vtPA
made as an MBP fusion protein grown in LB and EnBase media in shake flasks at 30°C. Nomenclature as per the previous panel.
Nguyen et al. Microbial Cell Factories 2011, 10:1
http://www.microbialcellfactories.com/content/10/1/1
Page 5 of 13
bodies (data not shown). A similar beneficial effect of
PDI expression on BPTI production in the periplasm of
wild-type E. coli, where endogenous DsbC is present,
has previously been reported [20].
All of the previous examples contain only intra-mole-
cular disulfide bonds, but inter-molecular disulfide bond
formation is important for many proteins. To examine
whether our system is able to make inter-molecular
disulfide bonded proteins we decided to examine pro-
duction of resistin. Resistin is a hormone linked to the
suppression of glucose uptake into adipose cells by insu-
lin [21]. The mature protein is only 90 amino acids in
size but it contains 5 non-sequential disulfide bonds and
an inter-molecular disulfide which links two resistin
monomers together to form a disulfide linked homodi-
mer. Expression of MBP-tagged resistin with a factor Xa
cleavage site in the linker region in BL21 (DE3) pLysS
resulted in the production and purification of negligible
soluble protein, while co-expression of Erv1p and DsbC
resulted in the purification of some soluble protein
(Figure 6A, compare lanes 1 and 2). Use of the origami
strain further increased the yields of soluble protein pro-
duced but a heterogeneous population of species was
obtained with the native dimeric state being in the min-
ority. In contrast, expression in origami with pre-expres-
sion of Erv1p and mature DsbC resulted predominantly
Figure 5 Production of BPTI in the cytoplasm of E. coli. Analysis
of mature BPTI wild-type and mutants which mimic the two
disulfide folding intermediates produced in the cytoplasm of
origami with pre-expression of Erv1p and PDI in LB media at 30°C.
Panel A) Coomassie stained SDS-PAGE. T = total E. coli lysate; S =
soluble fraction. The position of BPTI is marked with an arrow. Panel
B) rpHPLC analysis of purified BPTI mutants under conditions which
allow identification of the different folding intermediates. Upper
trace (displaced 50 mAU) C30A/C51A mutant, lower trace C14A/
C38A mutant. A single peak with the elution point being equivalent
to the relevant two disulfide containing wild-type folding
intermediate was obtained for both proteins.
Figure 6 Analysis of mature human resistin expressed in the
cytoplasm of E. coli at 30°C in LB. Panel A) Coomassie stained
SDS-PAGE analysis of purified MBPx-resistin indicates production of
the disulfide linked dimer increases with pre-expression of Erv1p
and DsbC in both wild-type and Δgor ΔtrxB strains. The molecular
weights (in kDa) of the markers (mw) are indicated as are the
positions of the monomeric and dimeric forms of MBPx-resistin.
Panel B) Coomassie stained SDS-PAGE analysis of mature resistin
produced in origami with pre-expression of Erv1p and DsbC. S =
soluble fraction of E. coli lysates; P = Purified MBPx-resistin from an
amylose column; D = Purified material that has been digested with
factor Xa to release MBP and resistin (marked with *). Note that
under non-reducing conditions the resistin is a disulfide linked
homo-dimer. The molecular weights (in kDa) of the markers (mw)
are indicated as is the position of MBP post digestion. The position
of the MBP-resistin fusion is indicated with an arrow.
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in the formation of resistin disulfide linked homodimers
(Figure 6A compare lanes 3 and 4). Analysis of these
species after purification using a one-step procedure
amylose resin revealed that >90% of the material puri-
fied was a resistin homodimer (Figure 6B) and an
Elmans assay revealed 0.02 free thiol groups per resistin
molecule. Furthermore, cleavage of the mature resistin
from the MBP using Factor Xa resulted in the produc-
tion of MBP and a disulfide-linked homodimer of resis-
tin (Figure 6B; note the relative size of MBP and resistin
means that the relative staining is more than four times
stronger for MBP for equivalent molar amounts of
protein).
In addition to the more detailed studies on the model
proteins PhoA [12], AppA [12], vtPA, BPTI mutants
and resistin, we wanted to screen a wider range of
human proteins to see if they could be made using the
same Erv1p plus disulfide isomerase pre-expression vec-
tors. These include production of:
i) Mature human Ero1a. The Ero1 family are ER-
resident sulfhydryl oxidases involved in disulfide
bond formation [22]. Human Ero1a contains multi-
ple disulfide bonds which play a role in catalysis,
regulation and some which are probably structural
in nature [23,24]. It is produced insolubly in BL21
(DE3) pLysSRARE and is predominantly insolubly
produced in origami unless expressed as a fusion
protein [24]. With pre-expression of Erv1p and
human PDI it is expressed solubly in a range of
media (Figure 7A)
ii) Mature human colony stimulating factor 3. CFS3
is a hormone that stimulates the production of gran-
ulocytes and stem cells [25] and is also known as
granulocyte colony-stimulating factor. It is used in
oncological and hematological applications. CSF3
contains two sequential disulfide bonds and one free
thiol group near the N-terminal of the protein. With
pre-expression of Erv1p and DsbC, when expressed
as an MBP-fusion protein it is expressed solubly in a
range of media (Figure 7A).
iii) Mature human bone morphogenic protein 4.
BMP4 is a cytokine that regulates the formation of
teeth, limbs and bones it plays a role in fracture
repair and it initiates human stem cell differentiation
to trophoblasts [26]. It contains three non-sequential
intra-molecular disulfide bonds along with one inter-
molecular disulfide bond. With pre-expression of
Erv1p and DsbC, when expressed as an MBP-fusion
protein it is expressed solubly in a range of media
(Figure 7A).
iv) The catalytic light chain of human enterokinase.
Enterokinase is a highly specific protease [27], used
Figure 7 Screening for the production of for other human
proteins using Erv1p plus a disulfide isomerase pre-expression
system. Panel A) Coomassie stained reducing SDS-PAGE analysis of
mature human proteins produced in the cytoplasm of BL21 (DE3)
pLysS with different growth media. T = total E. coli lysate S =
soluble fraction. The positions of the proteins are marked with
arrows. The data shown is from Ero1a with pre-expression of Erv1p
and mature PDI; MBP-tagged CSF3 with pre-expression of Erv1p and
mature DsbC and co-expression of Erv1p and mature PDI; MBPx-
tagged BMP4 with pre-and co-expression of Erv1p and DsbC; MBPx-
light chain of enterokinase Cys896Ser with pre-expression of Erv1p
and DsbC. Many other variants and combinations of pre- and co-
expression conditions have been tested (see additional file 2: Table
of vectors used in this study). For all four of these proteins under all
conditions tested there is a concomitant increase in the number of
disulfide bonds and yields of monomeric protein upon co- or pre-
expression of Erv1p and a disulfide isomerase. Panel B) Reducing
SDS-PAGE analysis of mature human proteins produced in the
cytoplasm of origami in EnBase media with pre-expression of Erv1p
and DsbC. T = total E. coli lysate, S = soluble fraction, P = protein
purified using an NTA-spin column or amylose column. The
molecular weights (in kDa) of the markers (mw) are indicated.
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academically to release fusion proteins and to
remove FLAG-tags from proteins. The catalytic light
chain, expressed here, is 235 amino acids in size and
contains four disulfide bonds plus a free thiol group
that forms an intra-chain disulfide bond in the full
length protein. With pre-expression of Erv1p and
DsbC, when expressed as an MBP-fusion protein it
is expressed in a partially soluble form in a range of
media (Figure 7A).
v) Mature human interferon a2. Interferon a2 is an
anti-viral protein produced by macrophages [28].
The mature human protein is 165 amino acids in
length and it contains four cysteine residues that
form two non-sequential disulfide bonds. When
expressed with or without a MBP-tag with pre-
expression of Erv1p and DsbC it is expressed solubly
and can be purified to homogeneity (Figure 7B).
vi) Mature human interleukin 17. Interleukin 17 is a
cytokine that induces the production of proinflama-
tory cytokines [29]. The mature human protein is
132 amino acids in length. It contains six cysteines
which are reported to form two non-sequential
intra-molecular disulfide bonds. When expressed
with a MBP-tag with pre-expression of Erv1p and
DsbC it is expressed solubly and can be purified to
homogeneity (Figure 7B).
While these have not all been fully characterized in
this system, the tests we have performed have all been
positive, resulting in increased soluble yields of these
disulfide bond containing proteins.
Discussion
Currently it is often difficult to produce disulfide bond
containing proteins, especially on a large scale. This
severely inhibits scientific progress in understanding a
myriad of mechanistic processes and imposes limitations
on the biotechnology industry for the production of
therapeutic proteins. The most common route for large
scale production of proteins that contain disulfide bonds
involves biosynthesis in the cytoplasm of E. coli. Here
there are no mechanisms for disulfide bond formation.
Due to this recombinant proteins are unable to attain
their native conformation and form insoluble inclusion
bodies. Inclusion body refolding is a widely studied field.
However, it can be costly, complex, time consuming and
is often inefficient. Alternative routes for producing dis-
ulfide bonded proteins such as periplasmic expression
or expression in the endoplasmic reticulum of eukar-
yotes also have drawbacks.
Current systems for making disulfide bonded proteins
in the cytoplasm of E. coli are based on the disruption
of the thioredoxin/thioredoxin reductase and glu-
tathione/glutathione reductase pathways present in this
cytoplasm [4-11]. We recently showed that by co-
expression of a catalyst of disulfide bond formation pro-
karyotic disulfide bond containing proteins could be
produced even without disruption of these reducing
pathways [12]. Here we further develop and test this
system for the production of eukaryotic proteins with
multiple disulfide bonds.
For proteins with only a few disulfide bonds e.g. PhoA
and AppA, we showed that the addition of a catalytic
system for the formation of disulfide bonds i.e. co-
expression of the sulfhydryl oxidase Erv1p, increased the
yields of active protein produced up to 1000-fold over
the wild-type E. coli control, with yields of up to 16
mg/L of culture [12]. Furthermore, the addition of a cat-
alyst for the formation of disulfide bonds is more effec-
tive than the removal of the reducing pathways for these
proteins i.e. BL21 (DE3) pLysSRARE with co-expression
of Erv1p generates significantly higher yields of active
disulfide bond containing PhoA or AppA than the
rosetta-gami Δgor ΔtrxB strain [12]. However, here we
show for proteins with more disulfide bonds e.g. vtPA,
we find consistently that production via co- or pre-
expression of Erv1p in a Δgor ΔtrxB strain background
is more efficient than in a wild-type background, pre-
sumably due to the lack of competition of the reverse
reduction pathway. For all proteins we have tested that
are able to show at least some folding to the native state
in E. coli, co-expression of Erv1p, plus a disulfide iso-
merase where needed, significantly increases the yield of
active and/or solubly produced protein independent of
the genetic background of the strain. In addition, the
system is not limited to the use of Erv1p, other sulfhy-
dryl oxidases can potentially be used. For example, we
have preliminary data showing that co-expression of
human Ero1a and PDI is able to catalyze folding of
vtPA in a Δgor ΔtrxB strain (Ero1a itself contains struc-
tural disulfides and active protein is not obtained in a
wild-type background, though soluble protein can be
made in BL21 through the pre-expression of Erv1p and
PDI; Figure 7A)
The use of a fusion partner e.g. MBP, to increase the
solubility of the folding intermediates also contributes
significantly to increasing the yields of disulfide bonded
proteins as does pre-expression of the folding factors
and the choice of media. In combination we are able to
get yields of active vtPA circa 800 fold higher than pre-
viously reported using DsbC co-expression in a Δgor
ΔtrxB strain. However, the system as reported here is
not perfect. For proteins with only a few disulfide bonds
the material can be produced in high yields and can be
homogenous, especially when a fusion partner is used.
However, resistin (with 5 disulfide bonds plus an inter-
molecular disulfide) is the most complex protein we
have been able to produce to near homogeneity to date.
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More complex proteins e.g. vtPA show greatly increased
levels of activity and/or disulfide bond formation but
homogeneous natively folded protein is not observed.
However, it is clear that optimization of the system in
terms of timing, levels and nature of the pre-expressed
folding factors e.g. which disulfide isomerase is used and
growth conditions can make significant differences to
the quality of the protein obtained and that this needs
to be optimized for individual proteins rather than the
use of standard expression conditions for all proteins
reported here.
Conclusions
By using the components of natural systems and expres-
sing a catalyst of disulfide bond formation and a catalyst
of disulfide bond isomerization we are able to establish
systems which allow for the efficient production of
eukaryotic proteins with multiple disulfide bonds in the
cytoplasm of E. coli. While the system still requires
future development, we are able to get yields of active
vtPA circa 800 fold higher than previously reported
using DsbC co expression in a Δgor ΔtrxB strain.
Despite the requirement for individual optimization for
more complex proteins our results opens up a wide
range of possibilities for the academic investigation of
structure/function relationships of a large body of pro-
teins whose production was previously a limitation and
potentially the production of disulfide bonded proteins
on an industrial scale.
Methods
Vector construction
Expression vectors (see additional file 2: Table of vectors
used in this study) were made by standard molecular
biology techniques.
Expression vectors for Erv1p, mature DsbC, mature
PhoA, mature AppA, mature PDI and mature BPTI
were constructed previously [12,30,31]. The gene for
mature MBP (Lys27-Thr392) was amplified by PCR
using a colony of E. coli XL1-Blue as a template. The
genes for the kringle 2 and protease domains of human
tissue plasminogen activator (vtPA; Gly211-Pro562),
mature human resistin (Lys19-Pro108), mature human
CSF3 (Ala30-Pro207), mature human BMP4 (Pro294-
Arg408), mature human Ero1a (Glu24-His468), human
enterokinase light chain (Ile785-His1019), mature
human interferon a2 (Cys24-Glu188) and mature
human interleukin 17 (Gly24-Ala155) were amplified
using IMAGE clones as templates.
Mature BPTI, human vtPA, human tissue factor lumi-
nal domain, human CSF3, human Ero1a, human entero-
kinase light chain and human interferon a2 were cloned
into a modified version of pET23a which includes an N-
terminal his-tag in frame with the cloned gene and an
additional SpeI site in the multi-cloning site between
the EcoRI and SacI sites. The resulting gene products
include the sequence MHHHHHHM- prior to the first
amino acid of the protein sequence.
Polycistronic vectors were constructed by taking frag-
ments encoding the folding factors from the pET23
based constructs which include the ribosome binding
site e.g. XbaI/X fragments and ligating them into the
SpeI/X cut plasmid encoding the protein of interest
(where X is an appropriate restriction site found in the
multi-cloning site after SpeI and not found in either
gene e.g. XhoI). After a single such ligation this gener-
ates a plasmid that contains a single transcription initia-
tor/terminator and hence makes a single mRNA, but
has two ribosome binding sites and makes two proteins
by co-expression from two translation initiation sites
(Figure 2A). This ligation results in the loss of the origi-
nal SpeI site. Transfer of a SpeI site after the second
gene into the new vector allows a third gene to be
cloned by the same method resulting in a tricistronic
vector which makes three proteins from a single mRNA.
Note that to clone mature human PDI into these poly-
cistronic vectors silent mutations were made in the two
internal XhoI sites in the gene.
A variety of MBP-fusion protein constructs were
made. All were based on the expression of mature MBP
(Lys27-Thr392) cloned NcoI/BamHI into pET23 d. At
the 3’ end of the MBP gene a variety of flexible linkers
were introduced. These were: i) NSSSNNNNHM; ii)
GSGSGSGSGSIEGRGSGSGSGSGSHM, allowing clea-
vage by Factor Xa and iii) GSGSGSGSGSDDDDKHM,
allowing cleavage by enterokinase, with all three having
a NdeI restriction site encoded by the terminal His-Met
to allow construction of the fusion protein. Several of
the proteins of interest were tested in two or more of
these MBP variants and for most no significant differ-
ences were observed between the variants. vtPA was
tested in all three variants and the activity obtained with
the first variant was significantly lower (circa 30%) than
for the other two under all conditions tested. Due to the
relative costs of the proteases the Factor Xa containing
linker version of the MBP-fusion protein construct was
our version of choice here (denoted MBPx) and all
fusion protein data shown here is that vector unless
otherwise stated.
The generation of the pre-expression vectors was
complicated due to the lack of suitable restriction sites
between our chosen host vector (pLysS), the pET23
based vectors we had already cloned our folding factors
into and the pBAD 102/D-TOPO vector (Invitrogen)
from which we cloned the arabinose promoter. pLysS
was chosen as the backbone for the pre-expression vec-
tor as it, or a derivative of it is already in all of our host
strains and it is fully compatible with co-transfection
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with many commercial expression vectors, not only
pET23. We would also have liked to clone this system
into pLysSRARE, but lack of available information on
this vector hampered us. pLysS was modified with an
NsiI site added at position 3071 and an AvrII site added
at position 3578. pBAD 102/D-TOPO was modified by
adding an AvrII site at 1089 a XbaI site at 316 and a
XhoI site at 796. The genes encoding for Erv1p or
Erv1p and mature DsbC or Erv1p and mature PDI were
digested XbaI/XhoI from a pET23 based plasmid and
cloned into the same sites in the modified pBAD102/D-
TOPO. Note that this takes the ribosome binding sites
from pET23 and removes a fragment from pBAD102/D-
TOPO that includes the ribosome binding site, his-
patch thioredoxin, enterokinase site, TOPO sites and V5
epitope. The genes of interest were then cloned NsiI/
AvrII from this vector into the modified pLysS. This
results in a modified pLysS that includes not only the
genes of interest under the pBAD arabinose promoter,
but also the araC gene for regulation.
Mutagenesis of plasmids was carried out using the
QuikChange site-directed mutagenesis kit (Stratagene)
according to the manufacturers’ instructions.
All plasmid purification was performed using the
QIAprep spin miniprep kit (Qiagen) and all purification
from agarose gels was performed using the Gel extrac-
tion kit (Qiagen), both according to the manufacturers’
instructions.
All plasmids generated were sequenced to ensure
there were no errors in the cloned genes (see additional
file 2: Table of vectors used in this study for plasmid
names and details).
Protein expression
For expression in LB media, E. coli strains containing
expression vectors were streaked out from glycerol
stocks stored at -70°C onto LB agar plates containing
suitable antibiotics to allow for selection (100 μg/ml
ampicillin for pET23 derivatives, 35 μg/ml chloramphe-
nicol for pLysS derivatives; with 10 μg/ml tetracycline
and 15 μg/ml kanamycin for selection of origami or
rosetta-gami strains). The next day one colony from
these plates were used to inoculate 5 ml of LB media,
containing suitable antibiotics, and grown overnight at
30°C, 200 rpm. This overnight culture was used to seed
a 50 ml culture of LB containing suitable antibiotics in a
250 ml conical flask to an optical density of 0.05 at 600
nm (OD600). The addition of FAD to the media is not
required for the production of active Erv1p and preli-
minary experiments suggestion such addition does not
increase the yield of active proteins generated in this
system. This culture was grown at 30°C, 200 rpm until
the OD600 reached 0.4 at which point protein produc-
tion was induced either by the addition of 0.5 mM
IPTG or for pre-induction of the folding factors by the
addition of 0.5% w/v arabinose followed 30 minutes
later by 0.5 mM IPTG. The cells were then grown for a
total of 4 hours post induction at 30°C, 200 rpm and
the final OD600 measured. The cells were collected by
centrifugation and resuspended to an OD600 equivalent
of 10 (based on the final OD600 of the culture) in 20
mM sodium phosphate pH 7.4, 20 μg/ml DNase, 0.1
mg/ml egg white lysozyme and frozen. Such normaliza-
tion allows for easy correction for differences in the
growth rates of the cultures and allows rapid equal total
protein loading of samples for activity assay and SDS-
PAGE analysis. Cells were lysed by freeze-thawing.
Where appropriate, the insoluble fraction was removed
by centrifugation and the soluble fraction removed
quickly to a new container. Cell lysates or soluble frac-
tions were stored frozen in 1 ml aliquots for further
experiments as repeated freeze-thawing clearly influ-
enced the results obtained in a protein dependent
manner.
For expression in EnBase media (Biosilta Oy, Finland)
E. coli strains containing expression vectors were
streaked out from glycerol stocks stored at -70°C onto
LB agar plates containing suitable antibiotics to allow
for selection. The next day three loopfuls of bacteria
from the region of single colonies were collected and
resuspended in 0.8 ml of EnBase media. This was used
to inoculate 25 ml of EnBase media (with thiamine,
magnesium and Enz I’m pre-added according to the
manufacturer’s instructions), containing suitable antibio-
tics in a 250 ml conical flask to an OD600 of 0.1. The
flask was then sealed with an oxygen permeable seal and
the bacteria grown for 15 hours at 30°C, 200 rpm. The
OD600 of the culture was measured to ensure correct
growth and the booster media added according to the
manufacturer’s instructions. Pre-induction of the folding
factors was performed by the addition of 0.5% w/v ara-
binose, the cells grown for 30 minutes and then the pro-
tein of interest induced with 0.5 mM IPTG and the
cultures grown for a further 23.5 hours and the final
OD600 measured. The post culture processing was as
per growth in LB media.
Note, in addition to the results shown here many of
the proteins of interest were also expressed under con-
ditions other than those listed above. Varying the condi-
tions altered the yields of active protein obtained,
sometimes in a protein dependent manner. However, all
of the results obtained from all conditions are consistent
with the results reported here. While these consensus
conditions may not be optimal for any individual pro-
tein in our system, they appear to be a good starting
point for screening for any protein in our system. Note
also that 30°C for growth was chosen as Erv1p is not
well expressed in an active form at 37°C and that
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growth of large numbers of cultures was more conveni-
ent for us at 30°C than at lower temperatures. Some
proteins, for example the luminal domain of tissue fac-
tor (data not shown), are expressed more homoge-
neously at lower temperatures, but the effect of
temperature, induction OD600, induction time or the
concentration of inducing agent has not been systemati-
cally tested for any protein.
vtPA activity measurements from lysates
vtPA activity was measured using a chromagenic sub-
strate, chromozyme t-PA peptide assay (Roche), using a
methodology similar that that recommended by the
manufacturer but adapted for a continuous assay in 96-
well plate format. Since this method showed slight varia-
tions in activity with time all of the vtPA activity mea-
surements were repeated using the same batch of
substrate and same buffers and that data is presented
here. 20 mg of substrate was dissolved in 4 ml of steri-
lized water to generate a 20× substrate stock solution.
10 μl of soluble fraction from cell lysates were added to
190 μl of substrate diluted in reaction buffer (100 mM
tris-HCl, 0.15% tween20; pH 8.5) to give a final concen-
tration that is 1× in a 96 well microtitre plate, thermally
equilibrated to 37°C. The absorbance at 405 nm was
measured at 3 minute intervals for 30 minutes to deter-
mine the rate of formation of the product. Background
rates from appropriate controls strains not expressing
vtPA were subtracted, with these being less than 5% of
the signals for any system where Erv1p and a disulfide
isomerase were co- or pre-expressed. For samples with
little vtPA activity 20 μl of soluble fraction from cell
lysates were added to 180 μl of 1× substrate (see addi-
tional file 1: Table of vtPA production and activity data).
Control samples tested with 10 and 20 μl of lysate
showed no significant differences in activity once nor-
malized for the volume of lysate used. It should be
noted that this assay format gives a very inaccurate mea-
sure for the production of vtPA with no co- or pre-
expression of vtPA in a wild-type E. coli background.
Furthermore, our vtPA constructs have different tags
than previously reported and our activity measurements
are made from E. coli lysates, both of which may affect
activity measurements and hence cross-comparisons to
available specific activity values are inappropriate. Hence
all of the data has been normalized to that produced
with co-expression of DsbC in a Δgor ΔtrxB background
i.e. the best system previously reported. More accurate
determinations of very low activities can be obtained
under different experimental conditions (more lysate
and much longer incubations), but Erv1p co- or pre-
expression strains cannot be assayed under these condi-
tions as the measurements go off scale. All samples
were measured at least in duplicate. The number of
samples (n) in Figures 1, 3 and 4 and Table 1 represent
independent bacterial cultures, each measured at least in
duplicate, implying the number of activity measure-
ments for each data point varied from 4 to 24.
Protein purification and analysis
Purification of hexa-histidine tagged proteins was per-
formed by standard immobilized metal affinity chroma-
tography using Ni-NTA columns (Qiagen) under native
conditions was performed according to the manufac-
turers’ instructions following clearance of the cell lysate
by centrifugation (10000 rpm, 15 minutes, 4°C).
Immobilized metal affinity chromatography of N-
terminal hexa-histidine tagged BPTI wild-type and
mutants was performed using a 5 ml HiTrap Chelating
HP column (GE healthcare). The soluble fraction of the
E. coli lysate was prepared by centrifugation (10000
rpm, 15 minutes, 4°C). This was then loaded onto the
HiTrap Chelating column which had been pre-charged
with Ni2+, washed and equilibrated with 3 column
volumes of 20 mM sodium phosphate (pH 7.4). After
loading the sample the column was washed with 3 col-
umn volumes of wash buffer (20 mM sodium phos-
phate, 50 mM imidazole, 0.5 M sodium chloride; pH
7.4) then 3 column volumes of 20 mM sodium phos-
phate (pH 7.4) before elution with 2 column volumes of
50 mM EDTA (pH 7.4). All buffers were filtered and
degassed before use.
Reverse phase high pressure liquid chromatography
(rpHPLC) analysis of BPTI wild type and mutants pro-
duced in our strains was performed on an ÄKTA FPLC
system (GE Healthcare) using a μRPC C2/C18 ST 4.6/
100 column: The column was pre-equilibrated in buffer
A (0.065% trifluoroacetic acid), before a 50 μl sample
was loaded to the system using automatic sample injec-
tion. The elution gradients used were: 20-30% buffer B
(90% acetonitrile, 0.05% trifluoracetic acid) over 3 col-
umn volumes followed by a column volume of 30% buf-
fer B, then 30-31% buffer B over 5 column volumes, 31-
45% buffer B over 5 columns volumes, 1 column volume
of 45% buffer B for 1 column volume and then 45-100%
buffer B over 3 column volumes. 0.5 ml fractions were
collected with a flow rate of 0.3 ml/min. All buffers
were filtered and degassed before use.
Purification of MBP-tagged proteins was performed
using amylose resin (New England Biolabs). Amylose
resin (500 μl for 5 ml of lysate) was packed into an
empty plastic column. The resin was washed twice with
2 ml of water and then equilibrated with 5 ml of 20
mM sodium phosphate buffer (pH 7.4). The soluble
fraction of the E. coli lysate was loaded on the column
and allowed to equilibrate at room temperature for 5
minutes. The column was then washed five times with
2 ml of wash buffer (20 mM sodium phosphate, 0.2 M
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sodium chloride pH 7.4). 150 μl of elution buffer
(20 mM sodium phosphate, 10 mM maltose, 0.2 M
sodium chloride, pH 7.4) was added and the column
allowed to equilibrate at room temperature for 5 min-
utes. The elution was repeated two more times.
For Factor Xa cleavage 5 μl of 10× Xa-buffer (New
England Biolabs) was added to 43 μl of protein solution
(in the MBP-purification elution buffer) with a final
amount of protein of circa 50 μg. 2 μl of 1 mg/ml Fac-
tor Xa (New England Biolabs) was added, mixed and the
solution incubated for 6 hours at room temperature.
The soluble and insoluble fractions were subsequently
analysed by reducing and non-reducing SDS-PAGE.
Elman’s assay for free thiol content were performed at
room temperature under denaturing conditions in
50 mM Tris buffer, 2 M Guanidine hydrochloride
(pH 8.0) using 0.073 mg/ml Elman’s reagent. The
change in absorbance at 412 nm was monitored after 15
minutes and the free thiol content calculated using a
molar extinction coefficient of 13600 M-1cm-1.
Additional material
Additional file 1: Table of vtPA production and activity data. Details
the vtPA activity data used to generate Figures 1, 3 and 4, including
sample details, number of samples for each expression condition, lysate
volume assayed, Δabsorbance values from the activity data and relative
activity.
Additional file 2: Table of vectors used in this study. Details the 59
plasmid vectors used in this study including plasmid name, the plasmid
backbone and details of the protein(s) produced.
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